Florence Vullierme

Florence Vullierme is a Partner at Remora Capital (the venture arm now operating as Remora Biotech), a Lausanne-based life-sciences investment group founded in 2010. Within the partnership she is the executive who contributes commercial and corporate expertise rather than the deep-science side of the house: her stated remit spans management, business development, finance, growth strategy, M&A and post-merger integration, with a specific focus on the Pharma & Cosmetics sector. On the firm's team she has been listed alongside Managing Partner Richard Groenendijk (also the group's CFO) and associate Aurélie Nicolas.

Remora is not a conventional fund but an evergreen holding and incubator that "finances and manages a portfolio of companies from discovery to clinical proof-of-concept." It was co-founded by Dr. Jean-Marc Le Doussal, a serial life-sciences entrepreneur who has spun several portfolio companies out of the platform. The group has operated under several closely related legal entities — Remora Capital SA, Remora Partners SA and Remora Biotech SA — registered around Lausanne and the Biopôle life-sciences campus in Epalinges (Route de la Corniche 2, CH-1066).

Vullierme's Pharma & Cosmetics specialization maps directly onto part of Remora's portfolio: the group backs not only oncology and immunotherapy assets but also aesthetic/dermatology plays such as Activen, which develops synthetic mini-proteins for anti-aging skincare and immuno-dermatology — exactly the pharma-meets-cosmetics intersection where her business-development and M&A experience is deployed.

*Note: "Vullierme" is a rare name shared by a Paris-based entrepreneur (Florence Thueux Vullierme, of Suricat Partners / M2CARE, femtech) whose public company records show no link to Remora or Switzerland; the two appear to be different people, so that unrelated activity is not attributed here.*

• Invests through Remora at the seed / earliest stages, financing companies "from discovery to clinical proof-of-concept" — i.e., science-founder support rather than late-stage growth rounds.
• Sector conviction: biotherapies and life-changing therapeutics — immunotherapy, vectorized/radio-immunotherapy, cell & gene therapy, and regenerative & aesthetic medicine.
• Her personal lens within the partnership is Pharma & Cosmetics, bringing operating and deal experience in management, business development, finance, growth strategy, M&A and post-merger integration.
• Geography: Swiss and French life-sciences ecosystems (Lausanne/Vaud and the Nantes/Paris biotech clusters), reflecting Remora's cross-border operating footprint.
• Because Remora incubates and actively manages its holdings, the "yes" is less a passive check and more a decision to build and operate a company — favoring founders open to hands-on operational and corporate-development partnership.